News

Technique to make CAR T-cells in vivo could transform cancer care
Instead of extracting T-cells and engineering them in a lab, researchers have delivered mRNA directly into circulating immune ...
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma
The FDA approves INCY's Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, its second approved indication.
Precision Medicine Online8h
Lyell Immunopharma Releases Data From Phase I/II Trial of CD19/20 Dual Targeting CAR T-Cell Therapy
Lyell Immunopharma announced new clinical data Tuesday from a Phase I/II trial of its dual-targeted CD19/CD20 CAR T-cell therapy for relapsed or refractory large B-cell lymphoma. The company ...
Managed Healthcare Executive3h
With Lenacapavir 'You've Basically Got a Vaccine.' But Reaching the People Who Would Benefit Is Difficult, Says Gates Foundation Expert
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...
Targeted Oncology5h
Overcoming Caregiver Barriers in CAR T-Cell Therapy Referrals in DLBCL
During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy caregiver challenges and referral ...
CoinDesk16h
Crypto Daybook Americas: Bitcoin Shrugs Off Fed, Mideast War, but Derivatives Flash Caution
The CoinDesk Policy & Regulation conference (formerly known as State of Crypto) is a one-day boutique event held in Washington on Sept. 10 that allows general counsels, compliance officers and ...